title: [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
abstract: Type 2 diabetes (T2D), often associated with arterial hypertension, represents a high risk of cardiovascular disease and nephropathy. Two clinical trials demonstrate the superiority versus a placebo of two antidiabetic drugs in patients with T2D and high cardiovascular risk : empagliflozin, an inhibitor of sodium-glucose type 2 (SGLT2) cotransporters, in EMPA-REG OUTCOME and liraglutide, an agonist of glucagon-like peptide-1 (GLP-1) receptors, in LEADER. Both medications showed a significant reduction in major cardiovascular events (-14 and -13 %, respectively), cardiovascular mortality (-38 and -22%), all-cause mortality (-32 and -15 %) and renal events (-39 et -22 %). The underlying protective mechanisms remain controverted. Ongoing studies should allow to decide whether the benefits are specific to each molecule or may be attributed to a class effect.
authors.affiliation: Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU Site Sart Tilman, Liège, Belgique.
authors.forename: A J
authors.initials: AJ
authors.lastname: Scheen
authors.affiliation: Service de Cardiologie, CHU Site Sart Tilman, Liège, Belgique.
authors.forename: L
authors.initials: L
authors.lastname: Piérard
authors.affiliation: Service de Néphrologie-Dialyse-Hypertension, CHU Site Sart Tilman, Liège, Belgique.
authors.forename: J-M
authors.initials: JM
authors.lastname: Krzesinski
authors.affiliation: Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Site Sart Tilman, Liège, Belgique.
authors.forename: N
authors.initials: N
authors.lastname: Paquot
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D003925:Diabetic Angiopathies / Q000401:mortality / Q000517:prevention & control*; D003928:Diabetic Nephropathies / Q000401:mortality / Q000517:prevention & control*; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000069450:Liraglutide / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D000069450:Liraglutide; C570240:empagliflozin
keywords:  Empagliflozin ;  Glucagonlike peptide;  Liraglutide ;  SGLT2 inhibitor ;  Type 2 diabetes ; 1 ; Cardiovascular risk 